User:Mr. Ibrahem/Exenatide

Exenatide, sold under the brand name Byetta and Bydureon among others, is a medication used to treat diabetes mellitus type 2. It is used together with diet, exercise, and potentially other antidiabetic medication. It is a less preferred treatment option after metformin and sulfonylureas. It is given by injection under the skin within an hour before the first and last meal of the day. A once-weekly injection version is also available.

Common side effects include low blood sugar, nausea, dizziness, abdominal pain, and pain at the site of injection. Other serious side effects may include medullary thyroid cancer, angioedema, pancreatitis, and kidney injury. Use in pregnancy and breastfeeding is of unclear safety. Exenatide is a glucagon-like peptide-1 receptor agonist (GLP-1 receptor agonist) also known as incretin mimetics. It works by increasing insulin release from the pancreas and decreases excessive glucagon release.

Exenatide was approved for medical use in the United States in 2005. A month supply in the United Kingdom costs the NHS about £82 for the daily injectable and £73 for the weekly injectable version as of 2019. In the United States the wholesale cost of this amount is about US$700 and US$789 respectively. In 2017, it was the 260th most commonly prescribed medication in the United States, with more than one million prescriptions.